Intellectual disability (ID) is a clinical sign reflecting diverse neurodevelopmental disorders that are genetically and phenotypically heterogeneous. Just recently, partial or complete deletion of methyl-CpG-binding domain 5 (MBD5) gene has been implicated as causative in the phenotype associated with 2q23.1 microdeletion syndrome. In the course of systematic whole-genome screening of individuals with unexplained ID by array-based comparative genomic hybridization, we identified de novo intragenic deletions of MBD5 in three patients leading, as previously documented, to haploinsufficiency of MBD5. In addition, we described a patient with an unreported de novo MBD5 intragenic duplication. Reverse transcriptase-PCR and sequencing analyses showed the presence of numerous aberrant transcripts leading to premature termination codon. To further elucidate the involvement of MBD5 in ID, we sequenced ten coding, five non-coding exons and an evolutionary conserved region in intron 2, in a selected cohort of 78 subjects with a phenotype reminiscent of 2q23.1 microdeletion syndrome. Besides variants most often inherited from an healthy parent, we identified for the first time a de novo nonsense mutation associated with a much more damaging phenotype. Taken together, these results extend the mutation spectrum in MBD5 gene and contribute to refine the associated phenotype of neurodevelopmental disorder. Keywords: MBD5; nonsense mutation; intragenic duplication; intellectual disability INTRODUCTION Methyl-CpG-binding domain 5 (MBD5) protein (OMIM *611472) is a member of the MBD protein family in which MECP2 (OMIM *300005) is involved in Rett syndrome, a prototypical neurodevelopmental disorder. MBD5 contains five non-coding exons at its 5 0 -end, followed by 10 coding exons. Two isoforms have been described, 1 the longer one contains 1494 amino acids and is encoded by exons 6-15, the second one contains 851 amino acids and is encoded by exons 6-9. Functional studies suggested that MBD5 is likely to contribute to the formation or function of heterochromatin. 1 Isoform 1 of MBD5 is highly expressed in brain and testis and isoform 2 is highly expressed in oocytes, which suggest a possible role in cerebral functions and in epigenetic reprogramming after fertilization. Recently, deletions encompassing MBD5, as well as intragenic MBD5 deletions have been identified in individuals with a phenotype of intellectual disability (ID), seizures, significant speech impairment, and behavioral problems. [2] [3] [4] [5] [6] [7] [8] In this study, we used pangenomic arraycomparative genomic hybridization (array-CGH) and capillary sequencing of MBD5 gene to investigate DNAs from patients with unexplained ID. We further extend the mutational spectrum of MBD5 with damaging intragenic duplication and nonsense mutation associated with a clinical spectrum of neurodevelopmental disorder.
INTRODUCTION
Methyl-CpG-binding domain 5 (MBD5) protein (OMIM *611472) is a member of the MBD protein family in which MECP2 (OMIM *300005) is involved in Rett syndrome, a prototypical neurodevelopmental disorder. MBD5 contains five non-coding exons at its 5 0 -end, followed by 10 coding exons. Two isoforms have been described, 1 the longer one contains 1494 amino acids and is encoded by exons 6-15, the second one contains 851 amino acids and is encoded by exons 6-9. Functional studies suggested that MBD5 is likely to contribute to the formation or function of heterochromatin. 1 Isoform 1 of MBD5 is highly expressed in brain and testis and isoform 2 is highly expressed in oocytes, which suggest a possible role in cerebral functions and in epigenetic reprogramming after fertilization. Recently, deletions encompassing MBD5, as well as intragenic MBD5 deletions have been identified in individuals with a phenotype of intellectual disability (ID), seizures, significant speech impairment, and behavioral problems. [2] [3] [4] [5] [6] [7] [8] In this study, we used pangenomic arraycomparative genomic hybridization (array-CGH) and capillary sequencing of MBD5 gene to investigate DNAs from patients with unexplained ID. We further extend the mutational spectrum of MBD5 with damaging intragenic duplication and nonsense mutation associated with a clinical spectrum of neurodevelopmental disorder.
SUBJECTS AND METHODS

Ascertainment of the patients
Patients with an unexplained developmental delay/ID as isolated symptom or in association with behavioral problems took part in a clinical diagnostic testing for genomic imbalance using array-CGH, following initial testing for karyotype (results normal), thanks to the national array-CGH network funded by the French Ministry of Health. To further elucidate the involvement of MBD5 point mutations, we collected a clinically defined cohort of 78 individuals with moderate to severe ID without a known genetic cause (genomic copy number variants larger than 200 kb were previously excluded) and with significant clinical overlap with 2q23.1 deletion syndrome, reminiscent of Angelman-like phenotype or Smith-Magenis-like syndrome. More specifically, we included patients with ID, severe speech impairment, seizures, behavioral problems and in particular with autistic-like features. Informed consents were available for all tested patients.
Array-CGH analysis
Microarray-CGH analysis was carried out using 44K or 105K-oligonucleotide array (Agilent Technologies, Santa Clara, CA, USA) as previously described. 9 The array was analyzed with the Agilent scanner and the Feature Extraction software (v9.5.3.1; Agilent Technologies). A graphical overview was obtained using the CGH analytics software (v3.5.14; Agilent Technologies).
Genomic quantitative PCR
Quantitative PCR (qPCR) was performed on genomic DNA, using an ABI PRISM 7500 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). We designed primer sets in MBD5 gene (all primer sequences used in this study are available on request). qPCR was carried out as previously described. 9 The RPPH1 gene was selected as the control amplicon. Validation experiments demonstrated that amplification efficiency of the control and all target amplicons were approximately equal. All samples were run in triplicate. The dosage of each amplicon relative to RPPH1 and normalized to control male DNA was determined using the 2 ÀDDCt method.
Genomic sequencing
MBD5 ten coding, five non-coding exons (NM_018328) and one evolutionary conserved region in intron 2 were PCR amplified using standard procedures (available on request). PCR products were then purified and subjected to sequencing using BigDye Terminator kit (Applied Biosystems).
mRNA isolation, reverse transcriptase-qPCR Total RNAs were isolated from PaxGen blood RNA tubes using RNeasy mini kit (Qiagen, Hilden, Germany). Family samples were collected for patients A and B (mother, father and brother). Male and female controls were collected for patients C, D and E. RNA was reverse transcribed through the use of random primers (Superscript, Invitrogen, Life technologies, Paisley, UK). Reverse transcriptase quantitative real-time PCR (RT-qPCR) was performed on an ABI PRISM 7500 Sequence Detection System (Applied Biosystems). We designed primer sets within MBD5 (available on request). RT-qPCR was carried out in a total volume of 20 ml containing 10 ml of SYBR Green Master Mix (Applied Biosystems), 0.4 mM of each primer and 5 ml of complementary DNA (cDNA). Thermal cycling conditions were 95 1C for 20 s, followed by 40 cycles with 95 1C for 3 s and 60 1C for 30s. The ESD and ABL1 genes were selected as control amplicons. Validation experiments demonstrated that amplification efficiency of control and all target amplicons were approximately equal. All samples were run in triplicate. The dosage of each amplicon relative to ESD and ABL1 and normalized to control male cDNA was determined using the 2 ÀDDCt method.
cDNA sequencing
Primers were selected in MBD5 exons. RT-PCR products were electrophoresed on agarose gels, purified with NucleoSpin Extract II kit (Macherey-Nagel, SARL, Düren, Germany) and sequenced using BigDye Terminator kit (Applied Biosystems).
RESULTS
Clinical reports
The clinical characteristics of individuals with MBD5-specific disruption are summarized in Table 1 .
Patients A and B are monozygotic twin sisters. The father and the two first siblings are healthy. The mother was treated for epilepsy but treatment was interrupted during pregnancies. They were born prematurely without fetal distress. Z-scores of birth weight and length were at À1, and head circumference was in the normal range. They were noted to have global developmental delay. Patient A sat independently at 16 months and walked at 2 years 6 months, patient B sat independently at 17 months and walked at 3 years. Both spoke only single words and presented with stereotypies and autistic features. A brain MRI was normal. At the age of 3 years 6 months, both heights were at À3 SD, whereas weights and head circumferences were in the normal range. There is a isolated nostril anteversion on facial examination ( Figure 1a ).
Patient C,a male proband, was born following an uncomplicated, full-term pregnancy. Parents were non-consanguineous and healthy. Family history is otherwise unremarkable. Neonatal adaptation was normal. Birth weight (3300 g), birth length (49 cm) and head circumference (37 cm) were within the normal range. He presented with hypospadias and developed multiple bronchiolitis. He had an inguinal hernia repaired. He was noted to have global developmental delay. He walked at the age of 22 months, and language milestones were delayed. At the age of 4 years, height was 99 cm (median), weight 15 kg (median) and head circumference 52 cm ( þ 1 SD). He presented with stereotypies. No specific dysmorphic facial features were observed. He had fifth finger clinodactyly. Although his intelligence had not been formally evaluated, his ID was estimated to be mild to moderate.
Patient D is the only child of healthy non-consanguineous parents. Pregnancy was uneventful to the exception of hemorrhage related to partial placental detachment at 3 months of gestation. She was born at term with normal growth parameters. Initial developmental milestones were reported normal. She walked at 19 months. The first words were pronounced at 13 months. Between 24 and 30 months of age, regression of language skills occurred with concomitant regression of response to social overture. She gradually developed problematic behavior, with stereotyped movements of the arms, and periods of hyperactivity and attention deficit. She was seen at the neuropediatric department at 2 years and 4 months and at 3 years and 6 months. There was no motor deficit. Slight symptoms of cerebellar syndrome were noted with oral dyspraxia. She was also seen at the outpatient genetics clinic at 3 years and 11 months. Growth parameters were within the normal range and clinical examination showed a round face, nostril anteversion and down-turned corners of the mouth (Figure 1a) .
Patient E is a 10-year-old boy first seen at the age of 14 months because of developmental delay. He is the second of three children of healthy unconsanguineous parents. Pregnancy was reported as normal. He was born at 40 weeks by cesarean section because of placenta praevia. Neonatal adaptation was normal. Birth weight (2560 g), birth length (48 cm) and head circumference (34.5 cm) were in the low normal range. Since the first days of life, parents reported feeding difficulties. The boy developed opisthotonos during the first months of life. Unmotivated laughter was also reported. When first seen at 14 months, sitting was unstable, hand movements were poor, and language was absent. Eye contact was reported as easy. Some jerky movements were described. Length, weight, and head circumference were at the 50th percentile. Craniofacial examination was not specific with slightly broad forehead. EEG and cerebral MRI were normal. A screen for metabolic abnormalities and methylation analysis for Angelman syndrome were normal. UBE3A gene analysis (Dr Moncla, Marseille) was normal. At the age of 2 years 7 months, there was still no verbal language. Hypotonia was severe without walking. He presented with generalized tonico-clonic seizures at the age of 4 years. Treatment with valproate was initiated. At the age of 8 years, clonus of both legs were reported, which was associated with tongue and mouth clonus. EEG reported focal spikes and spike-wave complexes in the frontal and temporal left area, leading to the diagnosis of partial epilepsy. He was last seen at the age of 10 years 3 months. Height was at 147.5 cm ( þ 2 SD), weight and head circumference were in the normal range. He stood independently for a short period of time but did not walk. There was no verbal language. His parents reported him as happy with very frequent smiles. Craniofacial examination showed unspecific hypotonic characteristics with long face, open mouth and slightly everted lower lip. Ear lobules were large (Figure 1a ). This region had never been described as a copy number polymorphism in the database of genomic variants (http://projects.tcag.ca/variation/?source=hg18). Except for polymorphic regions, no copy number alterations were observed in other chromosomes. Using qPCR analysis on genomic DNA from patients A, B, D and their respective parents, we confirmed the biological relationships and revealed that genomic imbalances arose de novo. For patient C, parental DNAs were not available. However, qPCR on his genomic DNA allowed determining more precisely the extent of the duplication from non-coding exon 5 to coding exon 10. We used Sanger sequencing to screen MBD5 for point mutations in the selected cohort of 78 individuals with ID. We identified a nonsense mutation (c.440C4G (p.Ser147*); NM_018328.3) within coding exon 4 in patient E (Figure 2a) . Analysis of parental DNA confirmed the biological relationships and de novo occurrence of the mutation. In this series of patients, we also detected nine variants in protein-coding exons, not annotated in dbSNP (build 137), three intronic variants, three synonymous variants and three missense variants. In evolutionary conserved region and non-coding exons, five different variations were found. Detailed Supplementary Tables I and II. When parental material was available, we were able to show transmission from a healthy parent in all cases. RT-qPCR analysis showed ( Figure 2b ): (i) a notable reduction of MBD5 expression for both sisters A and B and for patient D, (ii) a significantly increased level for duplicated MBD5 exons in patient C, and (iii) a normal level of expression for patient E. RT-PCR analysis in patient C, with forward primers in coding exons 8, 9 and 10 and reverse primer in exon nc5, coding exons 1 and 2 of MBD5, amplified different aberrant transcripts. Sequencing analysis of these fragments (Figure 2c) showed that all aberrant transcripts led to premature termination codon. For patient E, RT-PCR and sequencing analysis of exon 4 showed that both normal and mutated alleles were expressed (Figure 2a ).
Molecular investigations
) þ þ þ þ þ Language impairment 71.4% (5/7) þ þ þ þ þ Autistic-like symptoms 100% (14/14) þ þ À þ þ Stereotypic repetitive behavior 60% (3/5) þ þ þ þ À Sleep disturbances 50% (3/6) À À À À À Short stature 40% (2/5) þ þ À À À Microcephaly 0% (0/5) À À À À À Seizures 85.7%(6/7) À À À À þ Ataxia 0% (0/3) À À À þ À Craniofacial features 66.6% (4/6) þ þ À þ þ Hand/foot anomalies 66.6% (4/6) À À þ À À Urogenital abnormalities 0% (0/4) À À þ À À
MDB5 mutations in neurodevelopmental disorders
C Bonnet et al sequencing results are displayed in
DISCUSSION
Recently, Talkowski et al 10 suggested a mixed model of deleterious, fully penetrant MBD5 deletions causing a neurodevelopmental disorder associated with features of 2q23.1 microdeletion syndrome, and reduced penetrance missense variants that significantly increase risk for autism spectrum disorder. In our work, we identified five patients with de novo MBD5-specific disruption (for patient C, we are aware that parental DNA was not available to confirm de novo occurrence of the intragenic duplication) with clinical characteristics similar to previously reported patients 10 (Table 1) , mainly with psychomotor retardation/ID, language impairment, and autistic-like symptoms. For patients A, B, C and D the phenotype is overlapping, less specific than patients with 2q23.1 microdeletion, which includes more frequently microcephaly, small hands and feet, short stature, and broad-based ataxic gait. Developmental delay/ID is isolated in patient C, and associated with behavioral problems in patients A, B and D. Seizures were not observed in these four patients, at this time in development. At the opposite, the phenotype of patient E is much more damaging without walking and verbal speech at the age of 10 years. Three patients (A, B and D) had a deletion including the last exons of ORC4 and only the two first untranslated exons of the brainexpressed isoform 1 of MBD5. A similar deletion has been reported. 5, 10 Expression level of MBD5 mRNA in patients A and B was significantly reduced in comparison to their non-deleted parents, sister and brother. This result proves that heterozygous deletion of the two first non-coding exons of MBD5 isoform 1 specifically leads to extinction of its expression on deleted allele. Interestingly, two novel MBD5 genetic alteration types were identified, an intragenic duplication and a nonsense mutation. Patient C intragenic duplication affects non-coding exon 5 to coding exon 10 of MBD5. Transcriptional studies showed the presence of six aberrant transcripts, and sequencing analysis showed in each of these transcripts a premature termination codon (at the end of the coding sequence of exon 15, 21 bp after the start of exon 5, 19 bp after the start of exon 6) in favor of a modified MBD5 protein with putative altered function. Patient E de novo nonsense mutation leads to premature termination codon in MBD5 gene, and is predicted to result in a truncated protein that lacks the Proline-rich domain in addition to the putative nuclear localization signal. This mutation was not reported in the 1000 Genomes project (http://browser. 1000genomes.org/) or in dbSNP (builds 137). RT-PCR analysis showed a normal level of expression of MBD5, suggesting that RNA decay did not occur. Notably, MBD5 transcripts sequencing showed in vivo expression of both normal and mutated transcripts. Translation of this mutated transcript might lead to a truncated protein with a dominant negative effect or this aberrant protein with the lack of the putative nuclear localization signal might impair the protein function. Complementary functional studies will help to appreciate the pathogenicity of these mutations. This fully penetrant mutation represents 1.2% (1/78) of our selected cohort. Interestingly, a MBD5 frameshift mutation (c.150del (p.Thr52Hisfs*31); NM_018328.4), resulting in a premature stop codon has been reported in a patient with Kleefstra syndrome phenotypic spectrum. 11 This frameshift mutation, predicted to be deleterious, is in favor of the implication of MBD5 mutations in an extended spectrum of neurodevelopmental disorders. Finally, regarding MBD5 point mutations, missense variants have been reported, 2,10 mainly inherited from a healthy parent. We also identified in our selected cohort of patients (Supplementary Table I ) previously reported missense variants. More specifically, for two patients (33 and 64) we detected the variants p.1048Thr4Ile and p.Ile752Val, respectively, each inherited from a healthy parent. As suggested by Talkowski et al, 10 these variants might participate as a potential risk factor for autism spectrum disorder. In conclusion, these findings confirm the involvement of MBD5 mutations in neurodevelopmental disorders and extend the mutational spectrum of MBD5. Additional observations will be needed to establish fine genotype-phenotype correlations.
